Small airway pathology and bronchoreversibility in advanced emphysema

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 7, Issue 2, 2010, Pages 93-101

  Kim, Victor ^a   Pechulis, Rita M ^a   Abuel Haija, Mohammad ^a   Solomides, Charalambos C ^a   Gaughan, John P ^a   Criner, Gerard J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Airflow Obstruction; Airway Remodeling; Bronchodilator Reversibility; Chronic Obstructive pa (Pathology); Human Airway Smooth Muscle; Pulmonary Disease

Indexed keywords

BRONCHODILATING AGENT;

ADULT; ARTICLE; BASEMENT MEMBRANE; BREATHING MUSCLE; BRONCHIOLE; BRONCHODILATATION; BRONCHOREVERSIBILITY; CONTROLLED STUDY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; SMOOTH MUSCLE;

AGED; AIRWAY REMODELING; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PNEUMONECTOMY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 77951278973     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412551003631691     Document Type: Article

References (42)

1. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ, Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115:966-971.
2. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091.
3. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31:742-750.
4. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-664.
5. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:814-819.
6. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164:S28-38.
7. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5:478-485.
8. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073.
9. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, Van Der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
10. Miller MR, Hankinson J Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Van Der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26:319-338.
11. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, Van Der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26:511-522.
12. Macintyre N, Crapo RO, Viegi G, Johnson DC, Van Der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720-735.
13. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117.
14. Kim V, Criner GJ, Abdallah HY, Gaughan JP, Furukawa S, Solomides CC. Small airway morphometry and improvement in pulmonary function after lung volume reduction surgery. Am J Respir Crit Care Med 2005; 171:40-47.
15. Littell RC, Milliken GA, Stroup WW,Wolfinger RD. SAS System for Mixed Models. SAS Institute 1996.
16. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Statist 1981; 35:124-129.
17. Harter HL. Expected values of normal order statistics. Biometrika 1961; 48:151-165.
18. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:711-717.
19. Lams BE, Sousa AR, Rees PJ, Lee TH. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1518-1523.
20. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, Macklem PT. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298:1277-1281.
21. Baraldo S, Saetta M, Cosio MG. Pathophysiology of the small airways. Semin Respir Crit Care Med 2003;24:465-472.
22. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645-2653.
23. Hogg JC, Chu FS, Tan WC, Sin DD, Patel SA, Pare PD, Martinez FJ, Rogers RM, Make BJ, Criner GJ, Cherniack RM, Sharafkhaneh A, Luketich JD, Coxson HO, Elliott WM, Sciurba FC. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. AmJ Respir Crit Care Med 2007; 176:454-459.
24. Bosken CH, Wiggs BR, Pare PD, Hogg JC. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 1990; 142:563-570.
25. Nagai A, West WW, Thurlbeck WM. The National Institutes of Health Intermittent Positive-Pressure Breathing trial: pathology studies. II. Correlation between morphologic findings, clinical findings, and evidence of expiratory air-flow obstruction. Am Rev Respir Dis 1985; 132:946-953.
26. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148:1220-1225.
27. Petty TL, Silvers GW, Stanford RE, Baird MD, Mitchell RS. Small airway pathology is related to increased closing capacity and abnormal slope of phase III in excised human lungs. Am Rev Respir Dis 1980; 121:449-456.
28. Tiddens HA, Pare PD, Hogg JC, Hop WC, Lambert R, de Jongste JC. Cartilaginous airway dimensions and airflow obstruction in human lungs. Am J Respir Crit Care Med 1995; 152:260-266.
29. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152:1666-1672.
30. James A, Carroll N. Airway smooth muscle in health and disease; methods of measurement and relation to function. Eur Respir J 2000; 15:782-789.
31. Amrani Y, Panettieri RA, Jr. Cytokines induce airway smooth muscle cell hyperresponsiveness to contractile agonists. Thorax 1998; 53:713-716.
32. Grootendorst DC, Rabe KF. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1:77-87.
33. Xu X, Rijcken B, Schouten JP, Weiss ST. Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Lancet 1997; 350:1431-1434.
34. Laprise C, Boulet LP. Asymptomatic airway hyperresponsiveness: a three-year follow-up. Am J Respir Crit Care Med 1997; 156:403-409.
35. Taylor RG, Joyce H, Gross E, Holland F, Pride NB. Bronchial reactivity to inhaled histamine and annual rate of decline in FEV1 in male smokers and ex-smokers. Thorax 1985; 40:9-16.
36. Rijcken B, Schouten JP, Xu X, Rosner B, Weiss ST. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. AmJ Respir Crit CareMed 1995; 151: 1377-1382.
37. Finkelstein R,Ma HD, Ghezzo H, Whittaker K, Fraser RS, Cosio MG. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 1995; 152:267-276.
38. Nagai A, ThurlbeckWM, Konno K. Responsiveness and variability of airflow obstruction in chronic obstructive pulmonary disease. Clinicopathologic correlative studies. Am J Respir Crit Care Med 1995; 151:635-639.
39. Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, van de Woestijne KP, Brusasco V. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88:1989-1995.
40. Schermer T, Heijdra Y, Zadel S, Van Den Bemt L, Boonman-de Winter L, Dekhuijzen R, Smeele I. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med 2007; 101:1355-1362.
41. Walker PP, Calverley PM. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD 2008; 5:147-152.
42. Sciurba FC. Physiologic similarities and differences between COPD and asthma. Chest 2004; 126:117S-124S; discussion 159S-161S.